- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
24
Nonbacterial Infections
of the Genitourinary Tract
Ryan N. Fogg and Jack H. Mydlo
Fungal Infections
The presence of fungal infections in genitourinary organs has become a common occurrence with the continuing increase in immunocompromised populations, and improved critical care of the elderly. A variety of fungi, either opportunistic or pathogens endemic to a specific region, cause human disease. Thus, a working knowledge of the common fungal infections, their clinical manifestations, and an awareness of at-risk populations is essential to early diagnosis and aggressive treatment.
Several types of patients are particularly vulnerable to fungal infections. Patients in immunocompromised states such as transplant patients, AIDS, diabetes, malignancies, chemotherapy, and premature infants are more susceptible to opportunistic infections and are vulnerable to endemic fungal dissemination and invasion. Malnutrition such as with chronic alcoholics makes the patients less able to fight systemic infection. Prolonged antibiotic use creates an environment ideal for opportunistic fungal overgrowth.Finally,patients with indwelling invasive catheters including intravenous catheters, particular in patients receiving total parental nutrition (TPN), as well as with indwelling urinary catheters are at increased risk of colonization, infection, and potential dissemination of fungal organisms.1 In the critical care setting, it is common for all three states to be present,accounting for their increased prevalence in this setting (Table 24.1).
Candidiasis
Candidiasis in the critical care setting comprises 10% of infections2 increasing with prolonged ICU stay. Candiduria is often seen in patients with prolonged indwelling catheters and antibiotic use exceeding 12–14 days,3 but its presence in the urine may represent colonization or active infection. The persistence of candiduria in populations at risk can disseminate into systemic invasive infections with mortality of 15–25%.4 Most patients with candiduria will be asymptomatic1, but some may present with frequency, urgency, dysuria, or hematuria.Active infections in the bladder typically cause mucosal edema, erythema, and white patches visible on cystoscopy, but may invade the bladder wall resulting in emphysematous cystitis and fungal balls or bezoars with resultant bladder obstruction or rupture.5 Infection can spread by local extension, perforation, or hematogenously. Invasion into the prostate results in prostatic abscesses and emphysematous prostatitis.6 In addition, epididymitis, while rare, has been reported.7 Candidemia in the ICU setting is most commonly caused by hematogenous dissemination of candiduria.8 Urologic manipulation of patients with candiduria has been demonstrated to cause candidemia. This is a serious sequela and must be aggressively treated as overall mortality approaches 40%.9 Dissemination can progress to renal involvement by hematogenous spread or as an ascending infection with
C.R. Chapple and W.D. Steers (eds.), Practical Urology: Essential Principles and Practice, |
323 |
DOI: 10.1007/978-1-84882-034-0_24, © Springer-Verlag London Limited 2011 |
|
|
|
|
|
|
|
|
|
|
324 |
|
|
|
|
||||||||
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
||||||||
Table 24.1. risk factors for fungal infections |
and fluorescence in situ hybridization (FISH). |
|||||||||
Prolonged urinary catheters |
Local availability will determine the most appro- |
|||||||||
priate diagnostic method. |
|
|
||||||||
|
|
|
|
|||||||
central venous catheters |
While Candida albicans has been the major |
|||||||||
total parental nutrition |
organism of candidiasis, the emergence of non- |
|||||||||
albicans infections is becoming more prevalent. |
||||||||||
Malignancy |
||||||||||
Candida glabrata has emerged as a common |
||||||||||
HiV |
cause of |
candidiasis in |
elderly |
patients |
with |
|||||
underlying malignancies, Candida tropicalis is |
||||||||||
solid organ transplantation |
||||||||||
found in leukemia patients with neutropenia, |
||||||||||
Broad spectrum antibiotics |
and Candida parapsilosis is the most common |
|||||||||
diabetes mellitus |
cause of candidiasis among neonates.9 This dis- |
|||||||||
tinction is important as culture sensitivities are |
||||||||||
|
|
|||||||||
chemotherapy |
rarely performed in the hospital setting, and |
|||||||||
corticosteroids |
each species has unique spectrum of antifungal |
|||||||||
sensitivities. |
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|||
neutropenia |
|
|
|
|
|
|
|
|
||
acute renal insufficiency |
Aspergillosis |
|
|
|
|
|
||||
Hemodialysis |
Aspergilla is a ubiquitous fungus present in soil, |
|||||||||
|
|
|||||||||
Prematurity |
vegetation, decaying vegetation, dust, spices, and |
|||||||||
severe pancreatitis |
potted plants. In humans, Aspergillus fumigatus, |
|||||||||
A. flavus, and A. niger are opportunists causing |
||||||||||
gastrointestinal surgery |
||||||||||
disease in immunocompromised host.5,11 |
||||||||||
ileal conduits |
Infection typically begins in the respiratory tree, |
|||||||||
but may disseminate to extra pulmonary sites. |
||||||||||
alcohol abuse |
||||||||||
The most common genitourinary manifestation |
||||||||||
Malnutrition |
is renal aspergillosis, occurring in 12% of dis- |
|||||||||
cirrhosis |
seminated infections. Less common are pros- |
|||||||||
tatic, testicular, and adrenal involvement.12 |
||||||||||
intravenous drug abuse |
Renal infection may occur by hematogenous |
|||||||||
|
|
spread or ascending infection. Patients may |
||||||||
resultant pyelonephritis, abscesses, papillary |
present with hematuria, fevers, or flank pain due |
|||||||||
to obstructive uropathy.11 The sequelae of renal |
||||||||||
necrosis, renal failure, and obstructive uropathy |
||||||||||
aspergillosis |
include |
pyelonephritis, |
renal |
|||||||
by fungal bezoars. Patients may present with |
||||||||||
abscesses, papillary |
necrosis, and obstruction |
|||||||||
fevers, colicky flank pain, and pyuria.5,10 |
||||||||||
by fungus |
balls |
or |
necrotic renal material |
|||||||
The diagnosis of candidiasis can be demon- |
||||||||||
(Fig. 24.1). Diagnosis is by urine or tissue dem- |
||||||||||
strated in a number of ways. First, the patient |
||||||||||
onstration of microscopic birfurcate hyphae.13,14 |
||||||||||
population should be considered. In patients |
||||||||||
Mortality is 40–90% necessitating prompt diag- |
||||||||||
with immunocompromise and significant risk |
||||||||||
nosis and systemic treatment. Prostatic asper- |
||||||||||
factors (See Table 24.1), especially in the ICU |
||||||||||
gillosis |
presents |
with |
lower |
urinary |
tract |
|||||
setting, a low threshold must be maintained to |
||||||||||
symptoms and outlet obstruction and is typi- |
||||||||||
culture for Candida sp. Urine cultures are a |
||||||||||
cally diagnosed on histologic analysis of pros- |
||||||||||
mainstay of candiduria diagnosis, with colony |
||||||||||
tatic resection.Aspergillosis epididymo-orchitis |
||||||||||
counts greater than 10,000 generally considered |
||||||||||
has been reported requiring orchiectomy.5 |
||||||||||
positive for an active infection.5 Blood cultures |
||||||||||
|
|
|
|
|
|
|
|
|||
are an insensitive but specific measure of candi- |
|
|
|
|
|
|
|
|
||
demia.9 In addition to standard culture tech- |
Cryptococcosis |
|
|
|
|
|
||||
niques, a number of immunoassays are available |
|
|
|
|
|
|
|
|
||
and in development for diagnosis including the |
Cryptococcus neoformans is an opportunistic |
|||||||||
latex agglutination assay, beta-glucan assay, |
fungus found in bird excreta, soil, and decay- |
|||||||||
Enzyme-Linked ImmunoSorbentAssay (ELISA), |
ing matter. Cryptococcosis occurs in |
many |
325
nonBactErial infEctions of tHE gEnitoUrinary tract
a |
b |
Figure 24.1. renal aspergillosis. (a) coronal non-contrast ct images of left hydronephrosis and pyelonephritis in 64-year- old male with renal aspergillosis after lung transplant.
(b) intraoperative retrograde pyelogram of same patient during stent placement with multiple filling defects.
immunocompromised states but particularly in the AIDS population. Beginning as a pulmonary infection, it can disseminate typically to the nervous system and beyond. Caseating adrenal necrosis with resulting insufficiency has been reported.15 Renal involvement may be as high as 50% in disseminated cryptococcosis, causing a granulomatous pyelonephritis or renal abscesses with flank pain, fevers, hematuria, or pyuria on presentation. Prostatic involvement may be present in as many as one quarter of disseminated infections. Patients may be asymptomatic, present with prostatism or outlet obstruction and examination may mimic prostatitis or neoplasm.11,16 Particularly in the AIDS era, the prostate has become a reservoir of infection even after the disseminated infection has been cleared, thus becoming a source of future systemic infections.17 Penile lesions may occur in cryptococcosis, presenting as ulcers, pseudotumors, or necrotizing infections. Cryptococcal infections can be diagnosed by India ink stain, methenamine silver stain, as well as by serum antigen titers and latex agglutination tests.11
Blastomycosis
Blastostomyces dermatitidis is a fungus endemic to the Mississippi,Missouri and Ohio river basins, as well as moist soil near Lake Michigan. It begins as a self-limited pulmonary infection, but in immunocompromised populations it can disseminate into a systemic infections with genitourinary involvement reported in approximately 20% of patients. Most commonly, the prostate, epididymis, and testes are involved.18 Clinical manifestations range from asymptomatic infection to epididymo-orchitis, irritative voiding symptoms, urinary retention, and prostatic abscesses.19 Conjugal transmission from infected prostatic and spermatic secretions has been reported.20 Diagnosis can be made by demonstration of the fungi in tissue, semen or urine by culture, serum blastomyces A antigen, and ELISA.5
Coccidioidomycosis
Coccidioides immitis is indigenous to the arid desert regions of western USA and Mexico, preferring hot, dry soil with high saline content.
|
|
326 |
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
The primary infection is pulmonary and mild, |
Radiographic Findings |
|
but rarely disseminated infections occur. |
|
|
Patients at risk for systemic infections include |
The radiographic findings associated with fun- |
|
those with immunocompromised states, chil- |
gal infections of the genitourinary tract differ |
|
dren younger than 5 years, and adults greater |
based on the organ of involvement, but overall |
|
than 50 years old. Postmortem analysis of |
have broad similarities that will be present |
|
patients with disseminating infections revealed |
despite the specific organism. Adrenal necrosis |
|
renal involvement in 35–60% of patients, |
will appear heterogeneous and may present with |
|
17–22% with adrenal infections, 4.6–6% with |
enlargement, or calcification on CT scan. Renal |
|
prostatic infections, 6% with retroperitoneal |
abscesses may be present in the cortex or in the |
|
involvement,and 1–5% with scrotal infections.21 |
perinephric space seen best by contrast CT, MRI, |
|
Additionally, systemic allergic reactions can |
or ultrasound. Fungus balls or sloughed papilla |
|
occur due to the high antigenicity, causing cuta- |
may be present at any point along the course of |
|
neous manifestations similar to erythema |
the upper tracts and bladder and typically |
|
nodosum.11 Renal coccidioidomycosis presents |
appear as filling defects with or without hydro- |
|
as graunlomas or microabscesses and may |
nephrosis on intravenous pyelogram (IVP), CT, |
|
radiographically resemble tuberculosis with |
and ultrasound. Prostatic abscesses will be well |
|
renal calcifications, infundibular stenosis or |
visualized by CT or by transrectal ultrasound. |
|
“moth-eaten” calices.22 Prostatic infections can |
Scrotal abscesses and epididymo-orchitis are |
|
present with hematuria, pyuria, and bladder |
well demonstrated by scrotal ultrasound. Overall, |
|
outlet obstruction, and examination demon- |
the radiographic findings associated with fungal |
|
strates a tender indurated prostate.23 Scrotal |
infections may be nonspecific and difficult to |
|
manifestations can include abscesses, sinus |
distinguish from bacterial infections or malig- |
|
tracts, and epididymal graunlomas.21 Diagnosis |
nancy, but must be combined with a low thresh- |
|
can be made by culture of secretions, urine or |
old of suspicion in those populations at risk, and |
|
tissue, as well as by coccidioidal compliment |
with the variety of laboratory tests available |
|
fixation antibody titers, and latex agglutination |
diagnose the specific causative organisms.5,10 |
|
studies.5,24,25 |
|
Histoplasmosis
Histoplasma capsulatum has worldwide distribution with a predilection for the Mississippi and Ohio river valleys in soil infused with bird and bat excrement. Infection begins as a mild respiratory infection that can disseminate in the face of immunosuppression with spread to the liver, spleen, bone marrow, reticuloendothelial system, and genitourinary tract. Patients with disseminated infections may present with fever, cough, chest pain, weight loss, hepatosplenomegaly, and lymphadenopathy.26 Genitourinary manifestations occur most commonly in the adrenal glands, with additional sites including the kidneys, testes, and prostate.27 Adrenal involvement may result in insufficiency.28 Patients may also present with renal abscesses, penile ulcers, prostatitis with prostatic abscess, or epididymitis. Diagnosis is made by demonstration of the organism in culture or tissue, Wright-Giemsa-stained blood smears, as well as by serum antigen levels, complement fixation, or immunodiffusion.11
Treatment
Treatment of fungal infections of the genitourinary tract depends upon the specific organism in question as well as the site of infection (Table 24.2). Thus, treatment must be considered on an individual basis and typically with the assistance of the infectious disease specialists. Despite this, several important principles exist. Three classes of antifungal agents are available and include: Amphotericin B, generally considered the gold standard for disseminated fungal infections and may be administered parentally or by bladder irrigation; Fluconazole which may be given intravenously or orally though its effectiveness varies among organisms; and Caspofungin, an effective broad spectrum antifungal. Medication regimens may require different lengths and routes of administration. For example, disseminated infection generally requires systemic intravenous administration, and prostatic infection often requires extended periods of antifungal treatment spanning weeks to months. Antifungal infections often need to be combined with surgical
327
nonBactErial infEctions of tHE gEnitoUrinary tract
Table 24.2. treatment agents (adapted from Bartlett29) |
|
|
||
Pathogen |
Infection |
Agent |
Dose |
Duration |
antifungals |
|
|
|
|
candidaa |
Urinaryb |
fluconazole |
200 mg iV or Po |
7–14 days |
|
|
amphotericin Bc |
0.3–0.5 mg/kg/day iV |
|
|
|
|
50 mg in il sterile water at |
5 days |
|
|
|
42 cc/h bladder irrigation |
|
|
systemic |
fluconazole |
400–800 mg iV × 1 then Po |
2 weeksd |
|
infections |
|
|
|
|
|
amphotericin B |
0.7–1 mg/kg/day iV |
|
|
|
caspofungin |
70 mg iV daily then 50 mg |
|
|
|
|
iV daily |
|
aspergillosise |
|
amphotericin B |
1–1.5 mg/kg/day iV |
at least 10 weeks |
|
|
Voriconazole |
6 mg/kg q 12 h × 1 day then |
|
|
|
|
4 mg/kg iV q 12 h then |
|
|
|
|
200 mg Po Bid |
|
cryptococcus |
|
amphotericin |
0.7 mg/kg/day iV |
2 weeks then |
|
|
B + flucytosine then |
100 mg/kg/day |
|
|
|
fluconazole |
400 mg Po daily |
for 8 more weeks |
Blastomycosis |
|
itraconazole |
200 mg Po Bid |
6–12 months |
|
|
amphotericin B |
0.7–1 mg/kg/day |
6–12 weeks |
coccidioidomycosis |
|
itraconazole |
200 mg Po Bid |
at least 1 year |
|
|
fluconazole |
400–800 mg daily |
|
|
|
amphotericin B |
0.5–0.7 mg/kg/day iV |
|
Histoplasmosis |
|
itraconazole |
200 mg Po Bid |
6–8 months |
|
|
amphotericin B |
0.7–1 mg/kg/day iV |
10–12 weeks |
tuberculosis |
|
isoniazid |
5 mg/kg Po daily |
6–9 months |
|
|
+ Pyrazinamide |
15–30 mg/kg Po daily |
|
|
|
+ rifampin |
10 mg/kg Po daily |
|
|
|
+ Ethambutolf |
15–25 mg/kg Po daily |
|
|
|
+ Vitamin B6 |
50 mg Po daily |
|
schistosomiasis |
|
Praziquantel |
20 mg/kg Po Bid |
1 day |
filariasis |
|
albendazole |
400 mg Po x 1 |
|
|
|
+ ivermectin |
150 mg/kg x1 |
|
|
|
diethylcarbamazineg |
2 mg/kg Po tid |
2 weeks |
onchocerciasis |
|
ivermectin |
150 mg/kg × 1 |
semiannual × |
|
|
|
|
2 years, |
|
|
|
|
then yearly |
aagents and doses listed are for Candida albicans. other candida species will require consultation with infectious disease specialists for local sensitivities.
bisolated asymptomatic candiduria does not generally require treatment.
cdosages are for amphotericin B deoxycholate. alternative formulations will require alternative dosage regimens. dtreatment is for 2 weeks after the patient is afebrile and blood cultures are negative.
eitraconazole or caspofungin can be used as alternative agents. fcan discontinue ethambutol after 2 months if sensitivities permit.
gPatients with high microfilarial counts may have significant side effects and causes the mazzotti reaction in onchocerciasis.